Initial Statement of Beneficial Ownership (3)
June 15 2016 - 4:14PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Rothbaum Wayne P.
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/7/2016
|
3. Issuer Name
and
Ticker or Trading Symbol
Lion Biotechnologies, Inc. [LBIO]
|
(Last)
(First)
(Middle)
50 WEST 57TH STREET, 15TH FLOOR
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Street)
NEW YORK, NY 10019
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
3846280
|
I
|
By Quogue Capital LLC
(1)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Warrants (right to buy)
|
11/5/2013
(2)
|
11/5/2018
|
Common Stock
|
2000000
(2)
|
$2.50
|
I
|
By Quogue Capital LLC
(1)
|
Series B Preferred Stock
|
(3)
|
(3)
|
Common Stock
|
1932667
|
(3)
|
I
|
By Quogue Capital LLC
(1)
|
Explanation of Responses:
|
(
1)
|
The reporting person is the managing member of Quogue Capital LLC and so may be deemed to beneficially own such shares of common stock.
|
(
2)
|
The Warrants may be exercised at any time prior to November 5, 2018 upon the election of the reporting person; provided, that the reporting person may at any given time exercise only up to that number of Warrants so that, upon exercise, the aggregate beneficial ownership of the issuer's common stock (calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of the reporting person, is not more than 4.99% of the issuer's common stock then outstanding (subject to adjustment up to 9.99% solely at the reporting person's discretion upon 60 days' prior notice).
|
(
3)
|
The Series B Preferred Stock will be convertible into common stock upon approval of such conversion feature by the issuer's stockholders, and has no expiration date. Each share of Series B Preferred Stock will be convertible into one share of common stock, subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other recapitalization affecting the issuer's common stock.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Rothbaum Wayne P.
50 WEST 57TH STREET, 15TH FLOOR
NEW YORK, NY 10019
|
X
|
|
|
|
Signatures
|
/s/ Wayne P. Rothbaum
|
|
6/15/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024